Literature DB >> 8476717

Operating characteristics of pediatric continuous arteriovenous hemofiltration in an animal model.

H A Werner1, M J Herbertson, M D Seear.   

Abstract

Continuous arteriovenous hemofiltration (CAVH) is an increasingly popular technique in the care of critically ill children. The operating characteristics of the available circuits are largely unknown. Prior to introducing CAVH into our pediatric intensive care unit, we investigated the performance of three CAVH circuits: CAVH with postfilter dilution, CAVH with prefilter dilution (CAVHpre) and CAVH with dialysis counterflow. Using a neonatal lamb model, we measured filter blood flow (QB), ultrafiltrate rate (QU), arterial, venous and ultrafiltrate compartment pressures, oncotic pressure, plus urea levels in blood and ultrafiltrate fluid for the three CAVH circuit designs. Transmembrane pressure and urea clearance were calculated for various values of QB after varying a clamp on the arterial side of the circuit. The major finding, applicable to all circuits, was the wide variability of QB. Constant attention was required in order to obtain a consistent QB. Fluid clearance was effective with all three circuits. Urea clearance averaged 5-10 ml/min and was principally dependent on QU and independent of QB. The addition of dialysis counterflow did not increase urea clearance. The most convenient circuit we tested was CAVHpre, but the problem of unstable QB is common to all unpumped arteriovenous filtrate circuits. It is a major limiting factor in the practical application of this technology to critically ill children.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8476717     DOI: 10.1007/bf00864394

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  10 in total

1.  Clinical trials with predilution and vacuum suction: enhancing the efficiency of the CAVH treatment.

Authors:  A A Kaplan
Journal:  ASAIO Trans       Date:  1986 Jul-Sep

2.  Treatment of acute renal failure in an infant using continuous arteriovenous hemofiltration.

Authors:  K V Lieberman; L Nardi; J P Bosch
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

3.  Pump control of continuous arteriovenous haemodialysis.

Authors:  T D Peachey; R J Ware; J R Eason; V Parsons
Journal:  Lancet       Date:  1988-10-15       Impact factor: 79.321

4.  Continuous arteriovenous haemodialysis in critically ill patients.

Authors:  P E Stevens; B Riley; S P Davies; P E Gower; E A Brown; W Kox
Journal:  Lancet       Date:  1988-07-16       Impact factor: 79.321

5.  Treatment of acute renal failure in an infant by continuous arteriovenous hemodialysis.

Authors:  F K Assadi
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

Review 6.  Hemofiltration in children with renal failure.

Authors:  J F Pascual; J D López; M Molina
Journal:  Pediatr Clin North Am       Date:  1987-06       Impact factor: 3.278

Review 7.  Continuous arteriovenous hemofiltration in children.

Authors:  K V Lieberman
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

8.  Factors affecting urea clearance during continuous hemodiafiltration in the canine model.

Authors:  D T Hiyama; R G Weiss; F C Ryckman
Journal:  J Pediatr Surg       Date:  1989-08       Impact factor: 2.545

9.  Continuous arteriovenous renal replacement systems for critically ill children.

Authors:  G Zobel; E Ring; V Zobel
Journal:  Pediatr Nephrol       Date:  1989-04       Impact factor: 3.714

10.  Treatment of acute renal failure in newborns by continuous arterio-venous hemofiltration.

Authors:  C Ronco; A Brendolan; L Bragantini; S Chiaramonte; M Feriani; A Fabris; R Dell'Aquila; G La Greca
Journal:  Kidney Int       Date:  1986-04       Impact factor: 10.612

  10 in total
  1 in total

1.  Citrate anticoagulation in pediatric continuous venovenous hemofiltration.

Authors:  Nahum Elhanan; Peter Skippen; Gabrielle Nuthall; Gordon Krahn; Michael Seear
Journal:  Pediatr Nephrol       Date:  2003-12-11       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.